Genex Pharmaceutical, Inc.
GENX · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.42 | -0.15 | -0.15 | -0.01 |
| FCF Yield | 10.21% | 50.72% | 45.35% | 0.72% |
| EV / EBITDA | 6.01 | 2.36 | 2.79 | 10.73 |
| Quality | ||||
| ROIC | 4.21% | 12.43% | 18.00% | 37.97% |
| Gross Margin | 88.80% | 91.08% | 87.87% | 87.97% |
| Cash Conversion Ratio | 1.55 | 1.91 | 2.20 | 0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.12% | 1.24% | 794.31% | 1,329,412.32% |
| Free Cash Flow Growth | -55.09% | -14.47% | 1,539.03% | 287.61% |
| Safety | ||||
| Net Debt / EBITDA | -0.54 | -0.21 | -0.30 | -0.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.47 | 0.66 | 0.54 |
| Cash Conversion Cycle | -86.32 | 790.77 | 667.84 | 523.77 |